Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Fulcrum Therapeutics Inc FULC

Healthcare
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company’s clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX... see more

Recent & Breaking News (NDAQ:FULC)

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 10, 2023

Fulcrum Therapeutics to Participate at the Upcoming SVB Securities Global Biopharma Conference

GlobeNewswire February 8, 2023

Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

GlobeNewswire January 17, 2023

Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire January 17, 2023

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 13, 2023

Fulcrum Therapeutics Provides Business Update and 2023 Outlook

GlobeNewswire January 4, 2023

Fulcrum Therapeutics Announces CEO Transition

GlobeNewswire January 4, 2023

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 5, 2022

Fulcrum Therapeutics to Participate at Upcoming 2022 BofA Securities Biotech SMID Cap Conference

GlobeNewswire December 1, 2022

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 11, 2022

Fulcrum Therapeutics Announces Recent Business Highlights and Third Quarter 2022 Financial Results

GlobeNewswire November 8, 2022

Fulcrum Therapeutics Appoints Chief Medical Officer and Chief Scientific Officer

GlobeNewswire November 7, 2022

Fulcrum Therapeutics® to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Tuesday, November 8, 2022 at 8:00 a.m. ET

GlobeNewswire November 2, 2022

Fulcrum Therapeutics® to Participate at Upcoming November Investor Conferences

GlobeNewswire November 1, 2022

Fulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 ReDUX4 Study at the World Muscle Society (WMS) Congress in Halifax, Canada

GlobeNewswire October 12, 2022

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 7, 2022

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 9, 2022

Fulcrum Therapeutics to Participate at Upcoming September Investor Conferences

GlobeNewswire September 6, 2022

Fulcrum Therapeutics® to Participate at the Upcoming Stifel 2022 Biotech Summer Summit

GlobeNewswire August 16, 2022

Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock

GlobeNewswire August 15, 2022